title: Monocyte tissue factor response is decreased in patients with hyperlipidemia.
abstract: Monocytes are potent regulators of blood coagulation through the expression of tissue factor (TF) on stimulation and of tissue factor pathway inhibitor (TFPI), a selective inhibitor of TF pathway. As hyperlipidemia can modify some monocyte functions, we compared the TF and TFPI expression by circulating monocytes and the plasma TFPI levels between 65 healthy normolipemic controls and 38 nontreated hyperlipemic patients. TF and TFPI relationships with plasma lipoproteins are also examined. TF and TFPI expression were evaluated in peripheral mononuclear cells after isolation from blood by density gradient centrifugation and after short culture with or without lipopolysaccharide (LPS). TF and TFPI activity and antigen were measured in mononuclear cell lysates using amidolytic assay and enzyme-linked immunosorbent assay, respectively. TFPI activity and antigen were measured in plasma using the same methods. Plasma factor VII (FVII) activity and antigen were also determined. LPS-stimulated monocyte TF activity and antigen were lower in hyperlipidemic patients than in controls (0.0001<p<0.03). This decrease of monocyte TF expression in hyperlipidemic patients was not related to an increase of monocyte TFPI. Monocyte TF activity was negatively correlated to atherogenic fractions and positively correlated to protective fractions, specially after ex vivo LPS stimulation. Increased TFPI and FVII plasma levels were found in hyperlipidemic patients compared to controls. These results indicate an impairment of TF production by circulating monocytes from hyperlipidemic subjects, which is linked to the increase of atherogenic lipoprotein fractions. Further studies are required to elucidate the mechanism of this inhibition.
authors.affiliation: Laboratoire d'Hématologie, Centre Hospitalier Régional Universitaire and Institut Pasteur Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Rugeri
authors.forename: S
authors.initials: S
authors.lastname: Susen
authors.forename: J M
authors.initials: JM
authors.lastname: Bard
authors.forename: D
authors.initials: D
authors.lastname: Corseaux
authors.forename: V
authors.initials: V
authors.lastname: Gavériaux
authors.forename: P
authors.initials: P
authors.lastname: Devos
authors.forename: J M
authors.initials: JM
authors.lastname: Lecerf
authors.forename: P
authors.initials: P
authors.lastname: Duriez
authors.forename: B
authors.initials: B
authors.lastname: Jude
mesh_terms: D000328:Adult; D000367:Age Factors; D000941:Antigens / Q000097:blood; D015992:Body Mass Index; D001835:Body Weight; D018932:Chemokine CCL2 / Q000378:metabolism*; D005167:Factor VII / Q000032:analysis / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000378:metabolism*; D008055:Lipids / Q000097:blood; D008070:Lipopolysaccharides / Q000378:metabolism / Q000494:pharmacology; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000737:chemistry*; D013925:Thromboplastin / Q000032:analysis* / Q000187:drug effects / Q000276:immunology
chemical_list: D000941:Antigens; D018932:Chemokine CCL2; D008055:Lipids; D008070:Lipopolysaccharides; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D013925:Thromboplastin